Track market-moving stories before they get noisy

Now in its third dispatching season, Sunrun’s California distributed power plant delivers utility-scale capacity on demand through two state programs to support California's grid July 14, 2026 08:00 ET  | Source: Sunrun Inc.

SAN FRANCISCO, July 14, 2026 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced that its California distributed power plant will support the state’s electrical grid this summer with up to 425 megawatts of peak dispatchable capacity, making it one of the largest flexible energy resources in the state and largest residential distributed power plant in the nation.

Sunrun’s California distributed power plant has more than 80,000 households enrolled this year—representing more than 110,000 home batteries. The power plant launched in 2024 with 16,000 Sunrun customers enrolled. The current enrollment marks a fivefold increase in just two years. Sunrun customers are compensated for participating.

“As electricity demand continues to grow, Sunrun’s power plants represent one of the fastest, most cost-effective tools available to grid operators,” said Sunrun CEO Mary Powell. “Our California power plant leverages the flexible energy capacity sitting in tens of thousands of homes across California and is dispatched closest to where the energy is being consumed, putting downward pressure on prices and infrastructure needs.”

For the first time, Sunrun’s California distributed power plant will dispatch energy through two state grid service programs: the California Energy Commission’s Demand Side Grid Support program and the California Public Utilities Commission’s Emergency Load Reduction Program, which is operated under bilateral contracts between Sunrun and Pacific Gas and Electric Company and Southern California Edison.

Sunrun coordinates all dispatch operations to maximize grid reliability while providing a seamless experience to customers, who are only enrolled in one of the two programs. Sunrun is available to support California’s grid every day from 4 to 9 p.m., through the summer and fall months, when demand is highest and the grid is most constrained. In May and June, Sunrun conducted several dispatches using portions of its batteries in Northern and Southern California.

Last summer, Sunrun demonstrated how its distributed power plant assets deliver energy at a utility-scale capacity. During a historic dispatch event on July 29, 2025, multiple aggregators, of which Sunrun was the largest, provided enough energy to the grid to power more than half of the city of San Francisco during peak demand. During the dispatch event, Sunrun’s home batteries supplied an average of more than 360 megawatts over two hours.

“From coast to coast, Sunrun’s distributed power plants are delivering at scale just as the grid demands more capacity due to the AI buildout, domestic manufacturing, increased electrification, and a lack of new supply coming online,” said Sunrun President and Chief Revenue Officer Paul Dickson. “As we continue to rapidly grow our distributed power plant portfolio year over year, Sunrun is providing immediate value and capacity to help meet peak demand and is tailoring programs to meet a variety of grid conditions and unique needs.”

If operated as a single front-of-the-meter battery project, Sunrun’s California distributed power plant’s 425 megawatts of peak dispatchable capacity would rank it among the top 10 utility-scale batteries in California. But unlike traditional front-of-the-meter projects, Sunrun’s distributed power plant uses existing homes and infrastructure, avoiding the need for new land, new transmission lines, or lengthy interconnection processes. Distributed power plants can continue to grow over time while also providing participating customers with backup power and energy resilience.

About Sunrun
Sunrun Inc. (Nasdaq: RUN) is America’s largest provider of home battery storage, solar, and home-to-grid power plants. As the pioneer of home energy systems offered through a no-upfront-cost subscription model, Sunrun empowers customers nationwide with greater energy control, security, and independence. Sunrun supports the grid by providing on-demand dispatchable power that helps prevent blackouts and lowers energy costs. Learn more at www.sunrun.com.

Media Contact
Wyatt Semanek
Sr. Director, Corporate Communications
[email protected]

Investor & Analyst Contact
Patrick Jobin
SVP, Deputy CFO & Investor Relations Officer
[email protected]

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Sunrun’s expectations for its California distributed power plant, including expected enrollment, battery participation, dispatchable capacity, dispatch performance, customer compensation, program availability, grid reliability benefits, ratepayer benefits, cost savings, future growth, and Sunrun’s ability to enroll, retain, coordinate, and dispatch customers and batteries through grid services programs.

Words such as “believe,” “expect,” “anticipate,” “estimate,” “plan,” “continue,” “intend,” “target,” “project,” “potential,” “will,” “may,” “could,” and similar expressions identify forward-looking statements. These statements are not guarantees of future performance; they reflect Sunrun’s current views with respect to future events and are based on assumptions and estimates and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from expectations or results projected or implied by forward-looking statements.

These risks and uncertainties include, but are not limited to: Sunrun’s ability to enroll, retain, coordinate, and dispatch customers and batteries through its California distributed power plant and related grid services programs; the final number of participating customers and batteries, battery availability, battery performance, dispatch conditions, and Sunrun’s ability to deliver the expected peak dispatchable capacity; the timing, frequency, duration, and need for dispatches during periods of peak demand, elevated wholesale prices, heat waves, and other grid events; participation in, and requirements of, the California Energy Commission’s Demand Side Grid Support Program, the Emergency Load Reduction Program, and bilateral arrangements with PG&E and SCE; customer compensation and Sunrun’s compensation for dispatching batteries; Sunrun’s ability to support grid reliability, reduce peak demand, and achieve the anticipated customer, ratepayer, and grid benefits described in this release; and Sunrun’s ability to match or exceed prior distributed power plant performance. Additional risks and uncertainties are described under the caption “Risk Factors” in Sunrun’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission.

All forward-looking statements used herein are based on information available to Sunrun as of the date hereof, and Sunrun assumes no obligation to update publicly these forward-looking statements for any reason, except as required by law.

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including pharmacotherapy use, discontinuation, switching and treatment progression. The fi.

Key Takeaways: 

Space Ground System Solutions, Inc., a wholly owned Parsons’ subsidiary, secured a five-year, $245 million contract with the U.S. Naval Research Laboratory to advance mission-critical satellite ground systems software and operations.This award continues a 30-year legacy supporting the Blossom Point Tracking Facility.Parsons is a trusted provider of end-to-end space and ground system solutions, including mission engineering, DevSecOps, and secure software-defined architectures. CHANTILLY, Va., July 14, 2026 (GLOBE NEWSWIRE) -- Space Ground System Solutions, Inc (SGSS), a wholly owned Parsons Corporation (NYSE: PSN) subsidiary, announced today that it has been awarded a $245 million indefinite delivery, indefinite quantity (IDIQ) contract from the U.S. Naval Research Laboratory (NRL) to provide software development, sustainment, and operations support for critical satellite mission systems over a five-year period of performance.

Under the Blossom Point Tracking Facility Software and Operations Support contract, Parsons builds on its 30 years of continuous advancement of NRL’s government-owned applications: Neptune® Software for automated satellite command and control and ground equipment control and status, and the Virtual Mission Operations Center (VMOC®) for satellite mission management. The work includes designing, testing, maintaining, and enhancing mission-critical software modules, as well as providing configuration control and cybersecurity for space and ground systems supporting national security missions.

“Continuing our work with the Naval Research Laboratory underscores Parsons’ role in delivering resilient, mission-ready space capabilities,” said Rob McDonough, vice president of Space Operations Services at Parsons. “This award reinforces our demonstrated ability to engineer and sustain secure, software-defined mission systems that enable operational advantage in an increasingly contested space domain. We look forward to advancing innovation with NRL to ensure critical space assets remain agile, integrated, and mission focused.”

The U.S. Naval Research Laboratory is the Department of the Navy’s premier research institution and a leader in space science and technology. It has been instrumental in advancing space-based communications, surveillance, and national defense capabilities for decades. Through this partnership, Parsons will directly support NRL’s mission to innovate and transition cutting-edge technologies to operational use across the Department of War.

For more than 30 years, Parsons has been a leader in delivering end-to-end space and ground system solutions, including mission engineering, satellite communications, space domain awareness, and advanced command-and-control capabilities. The company’s expertise spans the integration of software-defined architectures, secure data transport, and real-time mission operations, enabling customers to maintain decision advantage across complex, multi-domain environments.

For more information about Parsons and its space capabilities, please visit parsons.com/space.

About Parsons
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law.

Media Contact:                                        
Angie Benfield        
+1 803.334.5277
[email protected]

Investor Relations Contact:
Dave Spille
+ 1 703.775.6191
[email protected]

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its second quarter 2026 earnings conference call on Thursday, August 6, 2026, at 7:30 a.m. CT (8:30 a.m. ET).  Second quarter 2026 results are scheduled to be published prior to the call at 6:30 a.m. CT (7:30 a.m. ET).

The conference call will be broadcast, and accompanying presentation slides will be available, at ATImaterials.com. To access the broadcast, visit ATImaterials.com and select "Conference Call." Conference call replay will be available on ATImaterials.com.

ATI: Proven to Perform.
ATI (NYSE: ATI) is a global producer of high performance materials and solutions for the aerospace and defense markets, and critical applications in electronics, medical and specialty energy. We're solving the world's most difficult challenges through materials science. We partner with our customers to deliver extraordinary materials that enable their greatest achievements: their products fly higher and faster, burn hotter, dive deeper, stand stronger and last longer. Our proprietary process technologies, unique customer partnerships and commitment to innovation deliver materials and solutions for today and the evermore challenging environments of tomorrow.  We are proven to perform anywhere.  Learn more at ATImaterials.com.

SOURCE ATI

Also from this source

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Sach336699 / Shutterstock.com

ON Semiconductor’s (NASDAQ:ON | ON Price Prediction) rebound has been one of the semiconductor sector’s more dramatic stories of 2026, and our proprietary model still sees room to run. The stock trades at $95.96 after a 77.21% year-to-date rally that cooled from a $134.92 52-week high.

Our 24/7 Wall St. price target for ON Semiconductor is $123.74, implying 28.94% upside over the next 12 months. The model’s rating is buy, with high confidence at 90%.

24/7 Wall St. Price Target Summary Metric Value Current Price $95.96 24/7 Wall St. Price Target $123.74 Upside 28.94% Recommendation BUY Confidence Level 90% From Cyclical Trough to AI Data Center Breakout ON has whipsawed investors. Shares sat at $48.11 last September and ripped to $125.90 by mid-June before pulling back 12.9% over the past month.

Q1 2026 confirmed the inflection: revenue of $1.513 billion topped expectations by 1.72%, non-GAAP EPS of $0.64 exceeded expectations by 4.03%, and non-GAAP gross margin recovered to 38.5% from a depressed 20.3% a year earlier.

CEO Hassane El-Khoury said the business has “moved beyond the cyclical trough on a path to recovery”, with AI data center revenue more than doubling year over year.

Why Bulls See a Breakout Above $133 The bull thesis rests on the AI data center curve and the silicon carbide EV cycle. Q1 AI data center revenue more than doubled YoY and grew more than 30% sequentially, while Power Solutions climbed 14% to $736.6 million.

EliteSiC design wins with Geely, NIO, and Xiaomi position ON for the 900V EV architecture shift, and PineBridge estimates data center equipment demand growing around 25% annually for the next four to five years. Under our bull case, ON reaches $133.10 in 12 months, a 38.7% total return.

_________________________________

What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)

__________________________________________

What Could Go Wrong The bear case starts with valuation. ON’s trailing P/E of 71 and forward multiple of 31 leave no cushion. Free cash flow fell 52.23% YoY in Q1, yet ON spent $345.7 million on buybacks, roughly 160% of free cash flow.

Barclays initiated with equal-weight and a $75 target, flagging automotive and China exposure. Bulls counter that the $329.3 million restructuring charge is non-recurring and non-GAAP margins already run near 38.5%. Our bear case still points to $98.65, roughly flat with today’s price.

How ON Compares to NXPI and TXN NXP Semiconductors (NASDAQ:NXPI) is the cleanest automotive-analog comp. NXPI trades at a forward P/E of 20 with a 27.7% operating margin and 12.2% revenue growth. ON’s forward multiple of 31 looks rich against that, but ON’s AI data center exposure is scaling faster.

Texas Instruments (NASDAQ:TXN) sets the industrial-analog benchmark. TXN’s forward P/E of 41 and operating margin of 37.8% show what mature scale looks like. ON sits between the two on multiples, which makes our $123.74 target look reasonable rather than aggressive.

Company Forward P/E Operating Margin ON Semiconductor 31 18.2% NXP Semiconductors 20 27.7% Texas Instruments 41 37.8% Verdict: Model Rates ON a Buy The 24/7 Wall St. price target for ON Semiconductor is $123.74, a buy with 90% model confidence. The tipping factor is margin recovery paired with AI data center acceleration. The bullish setup holds if Q2 delivers within the $0.65 to $0.77 EPS guide. The thesis weakens if free cash flow keeps deteriorating while buybacks continue at 160% of FCF.

Year 24/7 Wall St. Price Target 2026 $123.74 2027 $129.27 2028 $155.71 2029 $184.89 2030 $199.89 These projections assume ON keeps executing on silicon carbide EV design wins and AI data center power. Meaningful upside or downside could come from automotive cycle turns or China policy shifts.

If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a Few Simple Questions. 

Get Matched with Vetted Advisors 

Choose Your  Fit 

Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)  

Contact [email protected] for any questions or corrections.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AeroVironment To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in AeroVironment between June 25, 2025 and March 10, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AeroVironment, Inc. ("AeroVironment" or the "Company") (NASDAQ: AVAV) and reminds investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) AeroVironment understated the likelihood that it would imminently face competition from other vendors for the work it performed in connection with the SCAR program and the U.S. Space Force's ongoing efforts to modernize the SCN; (2) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding AeroVironment's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the AeroVironment class action, go to www.faruqilaw.com/AVAV or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the AeroVironment Securities Class Action Lawsuit:

What is the AeroVironment securities fraud lawsuit about?

The AeroVironment securities fraud lawsuit is a federal securities class action alleging that AeroVironment, Inc. (NASDAQ: AVAV) and its executives made false and misleading statements to investors by concealing that the Company faced imminent competition for its SCAR program contracts and overstating its business and financial prospects. As the truth emerged through a series of disclosures - including a U.S. government stop work order on January 20, 2026, a Space Force announcement that it was reopening the SCAR program on March 2, 2026, and AeroVironment's disclosure of a $151.3 million goodwill impairment and contract termination on March 10, 2026 - AVAV's stock price dropped sharply, causing significant losses for investors.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired AeroVironment (AVAV) stock between June 25, 2025 and March 10, 2026 - the Class Period - and suffered financial losses may be eligible to participate in the AeroVironment securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former AeroVironment employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff in the AeroVironment class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any AeroVironment investor who purchased AVAV stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 27, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased AeroVironment stock during the Class Period?

Investors who purchased AeroVironment (AVAV) stock between June 25, 2025 and March 10, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the AeroVironment securities class action is July 27, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/AVAV for more information.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased AeroVironment securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304979

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Contribution to flagship 6G projects underscores VIAVI's pivotal role in the next generation of connectivity

, /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today announced that it has been awarded $1.1 million in funding from the European Smart Networks and Services Joint Undertaking (SNS JU) and Horizon Europe to advance the SHIELD-6G project.

As telecom breaches increase in volume and the threat of quantum-enabled cyberattacks moves from theoretical to imminent, network security has become a strategic priority for operators, enterprises and governments worldwide. The SHIELD-6G project aims to develop a comprehensive AI-driven Cyber Threat Intelligence (CTI) platform for 6G networks with interoperable security, orchestration and regulatory compliance. VIAVI will develop digital twins using its TeraVM AI RAN Scenario Generator (RSG), enabling AI-driven security models to be developed, tested and validated ahead of the first commercial 6G signal going live.

As part of SHIELD-6G, VIAVI will use its AI RSG technology to support advanced security testing of 6G network environments, using AI to simulate, detect and analyze potential threats across the network. This includes generating realistic network datasets that enable intelligent anomaly detection and the continuous refinement of AI-based security mechanisms to ensure that vulnerabilities are identified and addressed before they can be exploited in live networks.

"Security for 6G networks has to be built in from day one, and that requires the ability to simulate, test and detect threats before a single commercial 6G signal goes live," said Ian Langley, Senior Vice President, Wireless, Security and Applications Business Unit, VIAVI. "Our AI RSG technology is already being used to provide the essential digital twin foundation required to better understand 6G propagation, improve energy consumption and reduce FR3 signal interference. SHIELD-6G takes that capability directly into the security domain, where the stakes are even higher. We're delighted to be involved in this latest collaboration at the forefront of global technological innovation."

SHIELD-6G is part of the highly competitive Horizon Europe SNS JU call to accelerate European 6G research and innovation, which selected 20 new 6G projects. VIAVI joins a European consortium coordinated by University College Dublin, working alongside global industry leaders including Ericsson, Nokia, THALES & THALES SIX, as well as network operators Telefónica and LMT of Latvia, bringing together the full chain of expertise needed to secure 6G networks end to end.

About VIAVI
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI Perspectives, LinkedIn and YouTube.

Media Inquiries:
Grand Bridges
Emma Jenkins
[email protected]
+1 415 800 4529

SOURCE VIAVI Solutions

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Calix between January 28, 2026 and April 21, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Calix, Inc. ("Calix" or the "Company") (NYSE: CALX) and reminds investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) that the Company's advanced supply of memory components was dwindling; (3) that, as a result, the Company was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On April 21, 2026, Calix reported results for the first quarter of 2026 earnings, including that "Non-GAAP gross margin was 57.2%, down 80 basis points sequentially." Further, the Company reported "gross margin guidance for the second quarter of 2026 is between 54.25% and 57.25%" and "[f]or the year, we expect our non-GAAP gross margin to decline between 50 and 150 basis points."

In the accompanying earnings call, the Company's CFO stated "advanced purchasing had allowed us to avoid higher memory component costs during the first quarter. However, that advanced supply has run its course, and we now face market prices."

On this news, Calix's stock price fell $6.93, or 13.98% to close at $42.65 per share on April 22, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Calix's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Calix class action, go to www.faruqilaw.com/CALX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Calix Securities Class Action Lawsuit:

What is the Calix securities fraud lawsuit about?

The Calix securities fraud lawsuit is a federal securities class action alleging that Calix, Inc. (NYSE: CALX) and its executives made false and misleading statements to investors by concealing that the Company's strong first quarter margins were artificially inflated by advanced purchasing of memory components, that its advanced supply of those components was dwindling, and that it would soon be forced to purchase memory components at rising market prices - creating significant negative margin pressure. As the truth emerged on April 21, 2026, when Calix reported Q1 2026 results and its CFO disclosed that "advanced supply has run its course" and the Company would "now face market prices," CALX's stock price fell $6.93 per share, or 13.98%, causing significant losses for investors.

Who may be eligible to participate in the Calix class action lawsuit?

Investors who purchased or acquired Calix (CALX) stock between January 28, 2026 and April 21, 2026 - the Class Period - and suffered financial losses may be eligible to participate in the Calix securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Calix employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Calix lawsuit?

A lead plaintiff in the Calix class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any Calix investor who purchased CALX stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 27, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Calix stock during the Class Period?

Investors who purchased Calix (CALX) stock between January 28, 2026 and April 21, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Calix securities class action is July 27, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/CALX for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304983

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in “pure” DLB and support selection of 50 mg TID for planned Phase 3 study in DLB

Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in DLB

New Phase 2 study showed an 80 mg twice-daily dose of neflamapimod met its primary safety, tolerability, and pharmacokinetic objectives, with encouraging secondary findings on clinical activity

BOSTON, July 14, 2026 — CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) presented new analyses this week highlighting insights into neflamapimod's treatment effects in DLB at the Alzheimer's Association International Conference (AAIC) 2026 in London. The analyses included treatment effects during the placebo-controlled portion of CervoMed’s Phase 2b clinical trial, as well as the impact of achieving higher plasma drug concentrations relative to placebo during the trial's extension phase. They also included pharmacokinetic-pharmacodynamic (PK-PD) relationships for neflamapimod and its effects on MRI measures of the underlying disease process in DLB.

“The analyses presented at AAIC provide consistent evidence across clinical, plasma biomarker, and imaging studies that neflamapimod has the potential to address the underlying cause of DLB and sharpen our understanding of the optimal dosing strategies to help achieve this outcome,” said Dr. John Alam, Chief Executive Officer of CervoMed. “These studies provide important insights for the implementation of neflamapimod’s planned Phase 3 trial, and we’re thrilled to be able to share them with the DLB community.”

Data presented at the conference included new analyses from the 159-patient Phase 2b RewinD-LB trial of neflamapimod, a 16-week randomized, double-blind, placebo-controlled study followed by a 32-week neflamapimod-only extension, as well as additional preclinical and clinical studies. Collectively, these analyses span neflamapimod's effects on disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy in DLB, along with the first data on the safety, tolerability, pharmacokinetics, and clinical activity of an 80 mg twice-daily (BID) dose.
Analyses Reinforce Observed Treatment Effect of Neflamapimod in “Pure” DLB and Support Planned Phase 3 Dose

In the placebo-controlled phase of the RewinD-LB trial, neflamapimod did not replicate the positive results seen in its earlier Phase 2a study, in which it improved outcomes on the Clinical Dementia Rating – Sum of Boxes (CDR-SB) scale versus placebo. CDR-SB is a scoring scale used to stage the severity of Alzheimer's disease and other dementias. The analyses presented at AAIC indicate that the failure of the study to replicate the Phase 2a results can be attributed to a combination of a higher-than-targeted proportion of patients with Alzheimer’s disease (AD) co-pathology (as determined by elevated plasma pTau181 levels at screening), and use of a neflamapimod drug product batch that did not achieve expected plasma drug concentrations. Specifically, exploratory analyses from RewinD-LB provide evidence that neflamapimod slowed worsening of DLB in patients with low plasma pTau181 and in those who achieved expected plasma drug concentrations.

Exploratory analyses of the placebo-controlled phase of RewinD-LB identified treatment effects favoring neflamapimod on CDR-SB, with a consistently improving treatment effect at progressively lower plasma pTau181 levels. The plasma pTau181 cut-off of <21 pg/mL has recently been identified in scientific literature as the optimal cut-off to exclude AD pathology. Further, the improvement relative to placebo observed in the subset of participants with pTau181 <21 pg/mL was limited to those patients who were above the median trough plasma drug concentration for the study as a whole.

These effects were also demonstrated by the extension-phase results, where a batch of capsules (DP Batch B) achieved higher plasma drug concentrations than the batch used during the placebo-controlled phase (DP Batch A). A within-participant comparison of DP Batch B demonstrated a significant improvement in change in CDR-SB compared to placebo (0.17 increase with DP Batch B during the extension vs. 0.95 with placebo in the same patients, p=0.005; NOTE: an increase in CDR-SB score indicates worsening of disease), while a within-subject improvement was not seen with DP Batch A.

Together, these analyses corroborate that the study's primary result was affected by the inclusion of patients with AD co-pathology and by lower-than-expected neflamapimod exposure in some patients. These findings support the patient population and dose selected for the Company’s planned Phase 3 trial in patients with DLB, for which the Company has gained alignment with US Food and Drug Administration (FDA), European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and Pharmaceuticals and Medicines Devices Agency.

Neflamapimod Demonstrated Durable Slowing of Basal Forebrain Atrophy

Over the 16 weeks of the placebo-controlled period of the RewinD-LB trial, neflamapimod-treated participants demonstrated increased right basal forebrain (BF) volume relative to placebo, as measured by structural and functional MRI. BF atrophy is the primary pathogenic driver of disease expression and progression in DLB. Right basal forebrain volume remained stable over 48 weeks (placebo-controlled phase + extension) in participants receiving neflamapimod in both phases and stabilized after treatment initiation in the extension in prior placebo recipients.

Increases in functional connectivity between the right BF and the right default mode network (DMN) were also observed during the neflamapimod-only extension. Disruption in BF-DMN connectivity, marked by abnormal activity in these regions, has been linked to neurodegenerative disorders such as DLB.

The laterality of the treatment effect is consistent with published data showing that, in DLB, the neurodegeneration is more advanced in the left basal forebrain, potentially allowing for positive treatment effects to be more achievable on the right side.

New PK-PD Analysis and Phase 2 Study Results for Neflamapimod 80 mg BID in DLB Strengthen Understanding of Dosing

PK-PD Analysis

A new analysis showed that a consistent pharmacokinetic-pharmacodynamic relationship has been observed across nonclinical and clinical studies of neflamapimod, with a plasma trough drug concentration (Ctrough) threshold (~4 ng/mL) associated with biomarker and clinical improvements. The 4 ng/mL plasma threshold exceeds the in vitro concentration necessary to produce neflamapimod's primary pharmacologic effect, inhibition of interleukin-1β neurotoxic signaling.

Across the Company’s trials in DLB, observed clinical outcomes with neflamapimod have tracked with the proportion of patients who achieved the plasma Ctrough threshold of ~4 ng/mL:

 % of Patients Achieving Ctrough
≥ 4 ng/mLObserved Clinical Outcomes40 mg BID
(Phase 2a only)25%No discernible activity40 mg TID Batch A
(Phase 2b)50%Marginal clinical activity, except potentially in those who achieve
Ctrough target40 mg TID Batch B
(Phase 2b)75%Demonstrated improvement on CDR-SB, CGIC and plasma GFAP
BID: twice daily; CDR-SB: Clinical Dementia Rating scale – Sum of Boxes; CGIC: clinical global impression of change; GFAP: glial fibrillary acidic protein; TID: three times daily

Based on the above findings, the dose for the Company's planned future trials has been selected to be 50 mg TID, which is expected to achieve at or above the plasma Ctrough threshold of ~4 ng/mL in approximately 90% of patients.

Phase 2 Study of Neflamapimod 80 mg BID in Patients with DLB

A separate study evaluated an alternative dose of neflamapimod, 80 mg BID, which met its primary objectives for safety, tolerability, and pharmacokinetics. The regimen was well tolerated, with no new safety signals identified over 24 weeks in 26 participants with DLB and achieved target trough plasma concentrations predicted to optimize p38α inhibition, though the increase in Ctrough observed relative to the 40 mg TID dose utilized in the Company’s prior clinical trials was not dose proportional.

"Our clinical study of neflamapimod 80 mg twice daily met its primary objectives for safety, tolerability and pharmacokinetics. Although the clinical findings should be interpreted cautiously because this was an open-label study, the findings on the secondary objective of clinical activity are also very encouraging and consistent with the findings in prior studies of neflamapimod in patients with DLB, showing stabilization of executive function and of global cognition and function, along with evidence of reduced neuropsychiatric symptoms," said Professor Frederic Blanc, the 80 mg BID study's principal investigator, professor of geriatrics, and neurologist at Strasbourg University Hospitals.

Evaluation of other exploratory clinical, plasma biomarker, and MRI endpoints is ongoing.

CervoMed’s poster presentations of the results described above will be accessible in the Events and Presentations section of CervoMed’s website, https://www.cervomed.com/, following the presentation.

About Dementia with Lewy Bodies

DLB is the second most common progressive dementia after AD, affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson’s disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.

About Neflamapimod

Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.

In nonclinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week neflamapimod-only extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Forward-Looking Statements

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, amyotrophic lateral sclerosis, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any, in DLB or any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

Contacts

Media:
Biongage Communications
[email protected]
202-330-3431

Investor Relations:
Argot Partners
[email protected]
212-600-1902

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, today announced it has been named to Selling Power Magazine's 60 Best Companies to Sell For 2026 list, marking the fifth consecutive year the company has earned the distinction. Selling Power evaluated more than 260 organizations across a broad range of criteria, including hiring and onboarding, sales training and enablement, diversity within sales organizations, AI transformation initiatives, and overall sales culture.

"At ABM, our success begins and ends with our people," said Sean Mahoney, Executive Vice President and President of Sales and Marketing at ABM. "We are committed to providing our sales professionals with the training, resources, and support they need to grow their careers while helping clients solve some of their most complex operational challenges. This recognition reflects the strength of our culture, our commitment to continuous improvement, and the dedication of our team to building trusted relationships and delivering meaningful results for our clients."

Selling Power's annual ranking recognizes companies that cultivate high-performing sales organizations and environments where sales professionals can thrive. The publication's proprietary evaluation process highlights organizations that demonstrate a commitment to continuous improvement through investments in people, technology, and sales enablement, helping teams adapt to evolving customer needs and deliver long-term success.

About ABM
ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and more efficient, enhancing the overall occupant experience. ABM serves a wide range of market sectors including commercial real estate, aviation, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.

For more information, visit www.abm.com.

Media contact:
Michael Valentino 
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f191a7dd-bb7b-4ec3-a234-1d4f78f8347e

Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has delivered a major expansion of its Davyhurst Gold Project inventory, lifting mineral resources by 75% to 3.69 million ounces and ore reserves by 159% to 610,000 ounces.

The updated mineral resource estimate stands at 56.5 million tonnes at 2.0 g/t gold, while the ore reserve totals 8.4 million tonnes at 2.3 g/t gold, net of 80,000 ounces of mining depletion to April 1, 2026.

Ora Banda said the expanded inventory strengthened the pathway towards a larger and longer-life production base at Davyhurst and supported its ambition to become a more than 300,000-ounce-per-year Australian gold producer.

Round Dam drives resource growth Round Dam was the standout contributor, with its open-pit mineral resource increasing 964% to 25.4 million tonnes at 1.6 g/t for 1.33 million ounces.

Successful exploration and resource definition drilling also supported a maiden Round Dam open-pit reserve of 3.7 million tonnes at 1.9 g/t for 223,000 ounces.

The Waihi open-pit and underground resource increased 114% to 7.3 million tonnes at 2.1 g/t for 482,000 ounces, including a maiden underground reserve of 825,000 tonnes at 3.8 g/t for 101,000 ounces.

Central Davyhurst reserves now total 4.7 million tonnes at 2.2 g/t for 332,000 ounces, comprising Waihi Underground, Waihi Open Pit and Round Dam.

Change to company MRE ounces.

Underground mines add further ounces The Riverina underground resource increased 18% to 8.7 million tonnes at 2.5 g/t for 689,000 ounces, while its reserve rose to 844,000 tonnes at 3.7 g/t for 100,000 ounces.

At Sand King, the underground resource increased 4% to 3.9 million tonnes at 2.9 g/t for 363,000 ounces.

Measured and indicated resources at Sand King rose 27% to 223,000 ounces, while the underground reserve increased 49% to 1.24 million tonnes at 3.2 g/t for 125,000 ounces.

The overall reserve base now includes five principal mining sources: Waihi Underground, Waihi Open Pit, Round Dam Open Pit, Sand King Underground and Riverina Underground, alongside low-grade material and stockpiles.

Exploration investment delivers rapid conversion Ora Banda invested about $75 million in drilling during FY2026, completing more than 310,000 metres of reverse circulation and diamond drilling.

Managing director Luke Creagh described the update as a “step-change result”, saying the program had materially strengthened the Davyhurst production platform.

“Our ability to discover new deposits, develop them into mines and keep growing them in rapid time is setting us apart and gives us a clear line of sight to our goal to become Australia’s next plus 300,000oz gold producer,” he said.

What’s ahead Ora Banda plans a further 340,000 metres of exploration and resource development drilling in FY2027, excluding grade control drilling.

The program will focus on extending known mineralisation at Round Dam, Little Gem and Sand King, while a maiden mineral resource estimate for Little Gem is scheduled for the first half of FY2027.

Simmons First National Corporation (NASDAQ:SFNC) will release its second quarter earnings report after the closing bell on Thursday, July 16.

Analysts expect the Pine Bluff, Arkansas-based company to report quarterly earnings of 52 cents per share, up from 44 cents per share in the year-ago period. The consensus estimate for Simmons First National’s quarterly revenue is $250.98 million. It reported $214.18 million last year, according to Benzinga Pro.

On June 9, Simmons Bank announced that Jim Recer has joined the bank as executive vice president, commercial regional executive.

Simmons First National shares gained 0.5% to close at $22.98 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying SFNC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Obchodníci s akciemi společnosti Citigroup dosáhli rekordních tržeb a postavili se do čela řady klíčových obchodních divizí společnosti, které překonaly očekávání Wall Streetu. Celkově čtyři z pěti hlavních divizí společnosti – bankovnictví, služby, trhy a správa majetku – překonaly odhady analytiků sestavené agenturou Bloomberg. Zisk na akcii činil 3,15 USD, čímž překonal všech 20 odhadů analytiků. Akcie banky nicméně v premarketu reagují poklesem o 2 %.

Tržby z obchodování s akciemi ve druhém čtvrtletí meziročně vzrostly o 45 % na 2,3 miliardy dolarů, což je o přibližně 11 % více než rekordní hodnota zaznamenaná v prvních měsících tohoto roku. Banka se snaží přilákat více hedgeových fondů, aby rozšířila tuto oblast svého podnikání, která je menší než u jejích hlavních konkurentů na Wall Street.

Stejně jako v jiných velkých bankách vydělali investiční bankéři Citi nejvíce od roku 2021, kdy pandemické otřesy a extrémně nízké úrokové sazby vyvolaly v celém odvětví vlnu obchodních transakcí. V této divizi dochází k personálním změnám na manažerských pozicích poté, co se v roce 2024 ujal vedení Vis Raghavan.

Jedná se o první výsledky od doby, kdy generální ředitelka Jane Fraserová v květnu představila nové cíle ziskovosti, které u akcionářů vyvolaly obecně optimistický pohled na směřování společnosti. Cena akcií se za posledních 18 měsíců téměř zdvojnásobila, zatímco Fraserová pokračovala v již několik let trvajícím zefektivňování globálních operací Citi.

Na květnovém dni investorů generální ředitelka Citi předpověděla, že rentabilita hmotného kmenového kapitálu Citi, klíčového ukazatele ziskovosti, dosáhne do roku 2031 přibližně 14 % až 15 %. Společnost ve druhém čtvrtletí vykázala 13 %, čímž překonala odhady analytiků ve výši 11,3 %.

To posiluje dynamiku obnovy banky, která minulý měsíc sklidila pochvalu od prezidenta Donalda Trumpa na sociálních sítích. Jeho syn Eric nedávno založil ve společnosti svěřenský fond s penězi svého otce. Fraserová vyvinula soustředěné úsilí o zlepšení vztahů své společnosti ve Washingtonu.

Přestože výsledky překonaly očekávání, 45% růst zaznamenaný divizí akciového obchodování Citi byl pomalejší než u jejích větších konkurentů, jako jsou JPMorgan a Goldman Sachs, které zaznamenaly růst o 86 %, respektive 72 %.

Ukazatel efektivity banky, který udává, kolik banka utratí za každý dolar vygenerovaných tržeb, klesl na přibližně 57 %, čímž se společnost přiblížila ziskovějším konkurentům, jako je JPMorgan, jehož ukazatel v prvním čtvrtletí činil 54 %.

Přesto segment spotřebitelských karet nedosáhl odhadů analytiků, protože náklady vzrostly o 10 % oproti předchozímu roku v důsledku vyšších nákladů na odstupné. Tato divize provádí reorganizaci části svého týmu v souvislosti s integrací části karetního portfolia společnosti Barclays ve spolupráci s American Airlines.

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended June 30, 2026, in a news release to be issued after the market close on Wednesday, July 29, 2026. Management will also host a conference call and live audio webcast at 5:00 p.m. Eastern Time to review the results. The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webcast will be available shortly after.

14.7.2026 14:13, BAC

Americká banka Bank of America zveřejnila výsledky hospodaření za druhé čtvrtletí roku 2026. Výnosy i zisk na akcii překonaly odhady analytiků, přičemž výrazně nad očekáváním skončily zejména výnosy z obchodování s akciemi bez vlivu DVA. Růst byl podpořen vyššími čistými úrokovými výnosy, silnou aktivitou v obchodování a vyššími poplatky z investičního bankovnictví.

Výsledky společnosti Bank of America (BAC) za 2Q 2026   2Q 2026 Konsensus 2Q 2026 2Q 2025 Výnosy (mld. USD) 31,56 30,49 27,44 Čistý zisk (mld. USD) 9,07 -- 7,17 Zisk na akcii (EPS, USD/akcie) 1,21 -- 0,90 Výsledky za 2Q Výnosy meziročně vzrostly o 15 % na 31,56 mld. USD, nad odhadem 30,49 mld. USD.

Čisté úrokové výnosy dosáhly 16,00 mld. USD (+9 % meziročně) a překonaly odhad 15,92 mld. USD. Čistá úroková marže dosáhla 2,08 %, v souladu s odhadem.

Čisté úrokové výnosy, zdroj: Bank of America

Výnosy z obchodování (bez DVA) dosáhly 7,16 mld. USD, výrazně nad odhadem 6,21 mld. USD. Z toho výnosy z obchodování dluhopisů, měn a komodit (FICC) činily 3,54 mld. USD (odhad: 3,53 mld. USD), zatímco výnosy z obchodování s akciemi dosáhly 3,62 mld. USD a výrazně překonaly odhad 2,69 mld. USD.

Celkové výnosy ze správy majetku a investic dosáhly 6,87 mld. USD, nad odhadem 6,61 mld. USD.

Výnosy z investičního bankovnictví činily 2,14 mld. USD a překonaly odhad 1,87 mld. USD. Poradenské poplatky dosáhly 558 mil. USD (odhad: 540,6 mil. USD), výnosy z dluhového financování 1,11 mld. USD (odhad: 958,7 mil. USD) a výnosy z akciového financování 535 mil. USD (odhad: 410,6 mil. USD).

Náklady na riziko (tvorba opravných položek) činily 1,37 mld. USD, pod odhadem 1,51 mld. USD. Čisté odpisy úvěrů dosáhly 1,41 mld. USD, mírně pod odhadem 1,43 mld. USD.

Náklady na riziko (tvorba opravných položek), zdroj: Bank of America

Personální náklady činily 10,99 mld. USD, pod odhadem 11,08 mld. USD. Celkové nepersonální náklady dosáhly 18,63 mld. USD, nad odhadem 18,35 mld. USD.

Rentabilita vlastního kapitálu (ROE) činila 12,7 % (odhad: 11,9 %), rentabilita aktiv (ROA) dosáhla 1,03 % (odhad: 0,96 %) a rentabilita hmotného kapitálu (ROTCE) činila 17 % (odhad: 15,9 %).

Objem úvěrů dosáhl 1,22 bil. USD, v souladu s odhadem. Celkové vklady činily 2,03 bil. USD, mírně pod odhadem 2,05 bil. USD.

Celkové úvěry a leasingy, zdroj: Bank of America

Kapitálový poměr CET1 dosáhl 12,5 %, v souladu s odhadem. Standardizovaný CET1 poměr činil 11,2 %, rovněž v souladu s odhadem.

Komentář CEO „Byl to jeden z našich nejsilnějších kvartálů, se ziskem na akcii vyšším o 34 % meziročně. Každý obchodní segment vykázal dvouciferný růst čistého zisku a silnou návratnost kapitálu. Výnosy vzrostly o 15 % oproti loňskému roku, jak jsme prohlubovali vztahy se stávajícími klienty a získávali nové. Byl to zároveň výjimečný kvartál pro naše segmenty zaměřené na trhy, kdy poplatky z investičního bankovnictví vzrostly o 50 % meziročně. V krátkodobém horizontu zůstává poptávka silná a komerční půjčování se zrychlilo. Disciplinované řízení nákladů spolu s investicemi do růstu pomohlo dosáhnout provozní páky 6,6 % a zlepšení efektivity o zhruba 360 bazických bodů oproti loňskému roku. Do budoucna se nadále soustředíme na to, co umíme nejlépe – sloužit klientům v každé fázi jejich finančního života,“ uvedl Brian Moynihan, předseda představenstva a generální ředitel Bank of America.

Návrat kapitálu akcionářům Společnost za druhé čtvrtletí vrátila akcionářům celkem 8,0 mld. USD, z toho 2,0 mld. USD formou dividend a 6,0 mld. USD prostřednictvím zpětného odkupu akcií.

Akcie Bank of America Akcie Bank of America (BAC) v předburzovní fázi obchodování klesají o 1,18 % na 58,80 USD.

Akcie Bank of America Corp (BAC) před výsledky uzavřely na 59,5 USD Ukazatel   Ukazatel   Kapitalizace (mld. USD) 422,2 P/E 13,7 Vývoj za letošní rok (%) +8,2 Očekávané P/E 13,2 52týdenní minimum (USD) 44,8 Prům. cílová cena (USD) 64,9 52týdenní maximum (USD) 60,8 Dividendový výnos (%) 1,9 Zdroj: Bank of America, Bloomberg

Michal Šnobl, Fio banka, a.s.

14.7.2026 14:21

Ropa +2,14 % na 79,81 USD za barel.
Zemní plyn -0,59 % na 2,88 USD za mbtu.

Zlato +0,75 % na 4035,7 USD za unci.
Stříbro +0,58 % na 58,31 USD za unci.
Měď +1,34 % na 6,365 USD za libru.

Kukuřice -1,19 % na 4,5775 USD za bušl.
Pšenice -0,55 % na 6,3175 USD za bušl.

Michal Šnobl
Fio banka, a.s.
Prohlášení

Chocolatey, marshmallow-flavored graham cracker dessert inspired by the campfire classic – no camping required

Highlights:

Domino's Rewards members will receive early access to the new dessert starting on July 20. S'mores Lava Cakes will roll out to all customers across the U.S. on July 27. S'mores Lava Cakes come in an order of three, or customers can build their own flight with Chocolate Lava Cakes. , /PRNewswire/ -- Domino's Pizza Inc. (Nasdaq: DPZ) is making it easier than ever to enjoy a classic campfire favorite with its newest indulgent dessert: S'mores Lava Cakes.

Domino's newest dessert, S’mores Lava Cakes, will roll out to customers across the U.S. on July 27, with Rewards members gaining exclusive early access on July 20. Each order of S'mores Lava Cakes comes with three decadent oven-baked graham cracker cakes oozing with a chocolatey chip and gooey marshmallow-flavored filling, and topped with a dash of powdered sugar – delivering the nostalgic taste of s'mores – no campfire required. Domino's Rewards members will receive exclusive early access to the new product, starting on July 20, with the dessert rolling out to everyone on July 27.

"Customers already love our Chocolate Lava Cakes, so we wanted to take that experience a step further with a flavor that's both nostalgic and irresistible," said Kate Trumbull, Domino's executive vice president – chief marketing officer. "S'mores Lava Cakes bring together everything people love about the classic treat – melty chocolate, gooey marshmallow and graham cracker flavor – without having to chop firewood, start a fire or apply bug spray."

Whether customers are rounding out their pizza night or simply craving something sweet, S'mores Lava Cakes offer a convenient way to enjoy a classic dessert without leaving the comfort of home – except for maybe an air-conditioned car ride to pick it up! A three-piece order of Domino's new dessert can be enjoyed through the Mix and Match deal for just $6.99. Higher prices may apply in certain locations.

Build Your Own Lava Cake Flight
With the launch of S'mores Lava Cakes, customers can now build their own flight by choosing between the new flavor and Domino's classic Chocolate Lava Cakes, which are oven-baked, filled with molten chocolate fudge, and topped with powdered sugar.

To sign up for Domino's Rewards and receive exclusive early access to S'mores Lava Cakes, visit dominos.com or download Domino's mobile app.

About Domino's Pizza®
Founded in 1960, Domino's Pizza is the largest pizza company in the world, with a significant business in both delivery and carryout. It ranks among the world's top public restaurant brands with a global enterprise of more than 22,300 stores in over 90 markets. Domino's had global retail sales of over $20.4 billion in the trailing four quarters ended March 22, 2026. Its system is comprised of independent franchise owners who accounted for 99% of Domino's stores as of the end of the first quarter of 2026. In the U.S., Domino's generated more than 85% of U.S. retail sales in 2025 via digital channels and has developed many innovative ordering platforms.

Order – dominos.com
Company Info – biz.dominos.com
Media Assets – media.dominos.com

SOURCE Domino's Pizza

SUGAR LAND, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of advanced optical and HFC networking products powering AI, today announced it has begun construction on its two adjacent properties in Pearland, Texas, adding nearly 400,000 square feet of manufacturing capacity.

The buildout of these properties, located at 14621 Kirby Drive and 11555 N. Spectrum Boulevard, supports AOI’s plans to increase production of its 800G and 1.6T optical transceivers, which are a critical component of modern AI infrastructures that let network devices communicate over fiber optics, enabling fast, long-distance data transmission.

“We are proud to be part of the Pearland business ecosystem and appreciate the level of support we received from the city and economic development offices to match our manufacturing needs,” said Dr. Stefan Murry, Chief Financial Officer and Chief Strategy Officer of AOI. “As we continue to grow and expand our Houston-area footprint, Pearland offers us access to a strong workforce, excellent infrastructure, and room to scale our operations. These facilities will be instrumental in supporting our long-term growth strategy, enabling us to expand production of advanced optical transceivers and strengthen AOI's position as a key supplier to the AI and cloud infrastructure markets.”

“We’re thrilled to welcome Applied Optoelectronics to Pearland as they expand their manufacturing footprint,” said Quentin Wiltz, Mayor, City of Pearland. “This project will bring high-quality jobs, strengthen our local economy, and deepen the innovation ecosystem that makes Pearland a destination for forward-looking companies. We look forward to continuing to support AOI as they grow and thrive in our community.”

Additional Resources:

AOI Optical TransceiversAOI Newsroom About AOI  
Applied Optoelectronics, Inc. (AOI) is a leading developer and manufacturer of advanced optical and HFC networking products that are the building blocks for AI datacenters, CATV and broadband fiber access networks around the world. AOI supplies this critical infrastructure to tier-one customers across cloud computing, CATV broadband, telecom, and FTTH markets. The company has R&D facilities in Atlanta, GA, and engineering and manufacturing facilities at its corporate headquarters in Sugar Land, TX, as well as in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com.

About PEDC
Established in 1995, the Pearland Economic Development Corporation promotes, assists, and enhances economic development activities and quality of life within Pearland, Texas. In bringing new and existing businesses to the area, the organization attracts capital investment to add to the city’s tax base and helps to increase the number of employment opportunities for residents. For more information, visit www.pearlandedc.com.

Media contacts:
Sara Cicero
[email protected]
770-331-0269

Melissa Cook
[email protected]
281-997-3003

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f8f49ccf-861c-4173-a6db-06fbdf54ccbb

Texas Construction Hat AOI Begins Expansion of Pearland Manufacturing Campus

Podobně jako JP Morgan či Bank of America hlásí silné hospodářské výsledky za letošní druhý kvartál také další americká banka Goldman Sachs. Ta zaznamenala rekordní čtvrtletí v obchodování s akciemi - výnosy zde meziročně vzrostly o 72 procent na rekordních 7,42 miliardy dolarů. Pozoruhodná je skutečnost, že se jedná už o třetí čtvrtletí v řadě, během něhož banka překonala v tomto segmentu své předchozí maximum.

Co se týče hlavních čísel, tak celkové tržby vzrostly meziročně o 39 procent na rekordních 20,34 mld. USD při konsenzu 16,35 mld. USD. Zisk na akcii činil 20,98 USD (+92 % y/y), což bylo rovněž výrazně nad odhadem ve výši 14,45 USD.

Banka uvedla, že růst podpořily jak příjmy z financování klientských pozic, tak z aktivit spojených s tvorbou a realizací investičních strategií. Pozitivně překvapilo také obchodování s úrokovými produkty, které se po slabším začátku roku vrátilo k růstu.

Významným zdrojem příjmů bylo také investiční bankovnictví. Poplatky za poradenství při fúzích a akvizicích, emise akcií a dluhopisů dosáhly 3,4 miliardy dolarů a rovněž překonaly očekávání analytiků. Šlo o nejsilnější čtvrtletí investičního bankovnictví Goldman Sachs od roku 2021.

Silné výsledky potvrzují pokračující oživení na trhu korporátních transakcí. Goldman Sachs patřila mezi hlavní organizátory některých nejvýznamnějších obchodů posledních měsíců včetně rekordního vstupu společnosti SpaceX na burzu a kapitálové transakce technologického gigantu Alphabet. Výnosy z akciového financování firem se meziročně více než zdvojnásobily.

Banka si zároveň upevňuje dominantní postavení na trhu fúzí a akvizic. Podle dostupných dat se letos podílela na transakcích v celkovém objemu přesahujícím jeden bilion dolarů a drží více než třetinový podíl na globálním trhu poradenství v oblasti M&A, píše Bloomberg.

Rekordní výsledky přicházejí v období, kdy investoři ve velkém přesouvají kapitál do technologických firem profitujících z rozvoje AI. Akciové trhy přitom pokračovaly v růstu navzdory geopolitickým rizikům spojeným s konfliktem na Blízkém východě. Index S&P 500 zaznamenal během čtvrtletí jeden z nejsilnějších výkonů za poslední roky.

Generální ředitel Goldman Sachs David Solomon již dříve uvedl, že na trzích aktuálně převažuje chuť riskovat nad obavami z možného zpomalení ekonomiky. Investoři podle něj aktivně vstupují do nových akciových emisí a využívají příznivého tržního prostředí.

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS), (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, announced today that it will voluntarily transfer the listing of its common stock, par value $0.0001 per share (“Common Stock”) to The Nasdaq Stock Market LLC (“Nasdaq”) from the New York Stock Exchange, effective after market close on July 24, 2026.D-Wave expects its Common Stoc.

Twenty-year triple-net (NNN) lease totaling $6.6 billion in contracted revenue, with up to $11.6 billion after full extension options

175 MW of critical IT load with deliveries expected to begin in Q4 2027 to a high-investment-grade tenant

Tenant has executed a letter of intent and exclusivity arrangement covering CleanSpark's entire Texas portfolio of 885 MW

, /PRNewswire/ -- CleanSpark, Inc. (Nasdaq: CLSK) ("CleanSpark" or the "Company"), a market leading data center developer, today announced it has entered into a 20-year infrastructure lease agreement, with two five-year extension options, directly with a high-investment grade, leading global technology company at its Sandersville, Georgia, campus. The lease is expected to generate approximately $6.6 billion of contracted revenue over the initial term.

Under the agreement, the global technology company will deploy production-grade infrastructure at Sandersville, dedicated to a range of computing workloads. In connection with the transaction, the tenant has also executed a letter of intent and exclusivity arrangement covering CleanSpark's entire Texas portfolio of 718 acres with up to 885 MW of secured and planned power capacity, positioning Sandersville as the first chapter of a substantially larger relationship.

"This lease is a transformational moment for CleanSpark as we complete our evolution into a diversified digital infrastructure platform and begin monetizing our power portfolio at institutional scale," said Matt Schultz, CleanSpark CEO and chairman. "A 20-year commitment from a high-investment-grade global technology company with a market-leading commercial profile and exclusivity across our nearly 900 MW of additional capacity in Texas is a tremendous validation of our land-and-power strategy. We have long believed in the second-mover advantage in this sector: grow our portfolio as the market matures, then execute with excellent terms and velocity. Today's announcement validates our thesis."

A Foundation Built at Sandersville

The Sandersville campus was selected for its access to reliable, low-cost power, available capacity for high-density compute, and its ability to support rapid, phased deployment of advanced data center infrastructure. Since the 2022 launch of its Sandersville operations, CleanSpark has established a sustained presence in the local community, investing in energy infrastructure, site development, and long-term operations that support economic activity throughout the region.

"CleanSpark has been a pillar of the Sandersville community for many years, providing job market stability, tax revenue, and broad support for what makes our part of the world special," said Mayor Jimmy Andrews. "We are excited to see CleanSpark embark on this new chapter and stand shoulder to shoulder with them to support this incredible infrastructure project."

While the tenant remains confidential, they are a global technology company among the high-investment-grade cohort, facilitating CleanSpark's financing options and the multi-decade term of the lease.

Transaction Details

Triple net (NNN) lease with annual escalators $6.6 billion of expected contract value across the initial 20-year term $11.6 billion of expected contract value if two five-year extension options are exercised Expected cumulative NOI contribution margin of nearly 100%, or an average annual NOI contribution of approximately $330 million Estimated landlord project costs of $10-$12 million per MW of critical IT load Texas Portfolio Under Exclusivity

Pursuant to the executed letter of intent, CleanSpark's entire Texas portfolio is now under exclusivity with the tenant. The Texas portfolio totals 718 acres with up to 885 MW of secured and planned power capacity, including 271 acres with nearly 300 MW at our Sealy campus and 447 acres at the Brazoria campus, where transmission-level infrastructure supports an initial 300 MW demand load with the potential to expand to 600 MW.

Advisors

Morgan Stanley & Co. LLC acted as financial advisor to the Company. Davis Polk & Wardwell LLP acted as legal counsel to the Company.

Conference Call

The Company will host a conference call on Tuesday, July 14 at 11 a.m. ET / 8 a.m. PT to discuss the announcement. Investors can join the live webcast at clsk.news/irupdatejul26.

About CleanSpark

CleanSpark (Nasdaq: CLSK), is a market-leading data center developer with a proven track record of success. We control a portfolio of more than 1.8 GW of power, land, and data centers across the United States powered by globally competitive energy prices. Sitting at the intersection of Bitcoin, energy, operational excellence, and capital stewardship, we optimize our infrastructure to deliver superior returns to our shareholders. Monetizing low-cost, high reliability energy by producing a global emerging critical resource – compute – positions us to prosper in an ever-changing world.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the estimated costs, contract value and NOI contribution (including as to the timing thereof) of the transaction announced in this press release and other statements regarding the Company's expectations, beliefs, plans, intentions, and strategies. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the Company's ability to timely achieve the lease agreement milestones for, among other things, obtaining financing for and completing the construction of the Sandersville data center project; the potential consequences of the Company not timely achieving the lease agreement milestones, which could include rent abatements and/or termination of the lease agreement; the Company's ability to meet all other covenants and conditions contained in the lease agreement; the Company's need for, and ability to raise, substantial additional capital to fund the development of the Sandersville project; risks related to the significant additional indebtedness that the Company may incur for purposes of such funding; the Company's dependence on a third party for development of the Sandersville project and the performance of such third party and its personnel and suppliers; the  ability to obtain the necessary equipment for the project on a timely basis and the competitive environment therefor; regulatory approvals and electrical power availability to complete the Sandersville data center project; the ongoing supply of electrical power to the project after the completion of construction and interruptions thereof; uncertainty as to whether the lease extension options will be exercised; natural disasters and other unforeseen events; changes to AI and HPC infrastructure needs; the risk that expectations of future revenue and NOI growth may not be realized; and other risks described in the Company's prior press releases and in its filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in those filings. Forward-looking statements contained herein are made only as to the date of this press release, and the Company assumes no obligation to update or revise any forward-looking statements as a result of any new information, changed circumstances or future events or otherwise, except as required by applicable law.

Investor Relations Contact
Kyle Sourk
702-989-7693
[email protected] 

Media Contact
Malory Van Guilder
[email protected]

SOURCE CleanSpark, Inc.

MCLEAN, Va.--(BUSINESS WIRE)--AIRO Group Holdings, Inc. (Nasdaq: AIRO)(“AIRO” or the “Company”), a next-generation aerospace and defense company, today announced that its RQ-35 Heidrun, developed through its drone brand, Sky-Watch, has been granted Blue UAS status by the Defense Contract Management Agency (DCMA). With this approval, the RQ-35 is recognized by the Department of War (DoW) as a secure, compliant unmanned aircraft system eligible for government and defense acquisition under NDAA re.

July 14, 2026 07:00 ET  | Source: USA Rare Earth, Inc.

Positions USA Rare Earth as one of few companies outside of Asia with the capability to separate heavy rare earths

Represents important step toward an integrated value chain that secures global supply for advanced manufacturing and critical industries

Broadens Company’s feedstock options to include recycled material, complementing planned oxide production from Round Top and Serra Verde concentrates

Samples to be sent to LCM for qualification; produced oxides to serve as feedstock to rare earth metal production, which supplies the Company’s magnet manufacturing facilities in the United States

WHEAT RIDGE, Colo., July 14, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) ("USAR", "USA Rare Earth", or the "Company"), a rare earth, critical minerals and advanced materials company, today announced that its hydrometallurgical facility in Wheat Ridge, Colorado, has produced commercial-grade dysprosium (Dy) oxide and neodymium-praseodymium (NdPr) oxide samples from recycled rare earth magnet scrap, known in the industry as "swarf."

USA Rare Earth’s successful separation of commercial-grade Dy oxide and NdPr oxide at Wheat Ridge is a pivotal milestone, establishing the Company as one of the few Western producers capable of executing this technically demanding process outside Asia. By bridging world-class upstream resources with advanced separation and processing, metallization, and magnet manufacturing, the Company’s mission is to build the leading global rare earth and critical mineral value chain where each link reinforces the next. This achievement marks a critical step toward delivering a global, integrated solution to de-risk supply chains for defense, semiconductors, and physical AI infrastructure.

The Dy and NdPr oxides were produced using swarf, the fine scrap generated when neodymium-iron-boron (NdFeB) magnets are machined and finished, which in this case were sourced from the Company’s Stillwater, OK magnet manufacturing facility. Turning that scrap back into high-purity light and heavy rare earth oxide broadens the Company’s feedstock options and strengthens the circularity of its value chain, with swarf projected to support up to 30% of future magnetic rare earth oxide feedstock needs. This validation of the magnet swarf recycling flowsheet also lays the foundation to potentially incorporate end-of-life magnets as an additional commercial feedstock option.

The oxides produced at Wheat Ridge are expected to be sent to Less Common Metals (“LCM”), USA Rare Earth’s subsidiary in the United Kingdom, for qualification and for conversion into rare earth metals and strip cast. The output from LCM, which is one of the few commercial scale metal, alloy and strip cast producers outside of Asia, is expected to serve as feedstock for the Company’s magnet manufacturing facilities in the United States.

Dysprosium is one of the most technically challenging rare earth elements to separate at commercial purity, and today virtually all Dy oxide is produced in China. While NdPr provides the magnetic foundation of NdFeB permanent magnets, dysprosium is added in smaller quantities to allow magnets to retain performance and coercivity at high operating temperatures, a requirement of the aerospace, defense, electric vehicle, robotics and industrial motor applications that NdFeB magnets enable. Producers with the proven ability to separate heavy rare earths at commercial specification outside Asia remain scarce, and Dy availability is widely recognized as a primary constraint on the Western permanent magnet industry.

Today’s production milestone places USA Rare Earth in that small group and establishes swarf from magnet manufacturing as a feedstock stream back into the Company’s value chain, closing the loop between the Company’s downstream magnet manufacturing and its upstream separation. Additional campaigns underway at Wheat Ridge are expected to process material from the Company’s Round Top project and from Serra Verde’s Pela Ema mine. These campaigns are expected to produce additional varieties of rare earth and critical mineral oxides in the coming weeks, further advancing USA Rare Earth toward proven capability across every stage of the rare earth value chain: mining, separation and processing, metal and alloy making, and permanent magnet manufacturing.

About the Wheat Ridge Facility

The Wheat Ridge demonstration facility runs 24 hours a day and is fully instrumented for real-time process monitoring across every unit operation. The facility is built to digitally and physically simulate the Company’s future commercial-scale operation, and the data it generates flows directly into the engineering design of a planned consolidated separation facility, which will process both magnet swarf and mixed rare earth carbonate (MREC). This allows the team to validate its proprietary flowsheets and refine the commercial design using live operating data and physical testing rather than theory alone.

About USA Rare Earth, Inc.

USA Rare Earth, Inc. (Nasdaq: USAR) is building a fully integrated rare earth and permanent magnet value chain across the United States and the United Kingdom, with plans for expansion in France and Brazil. Through its ownership of Less Common Metals (LCM), one of the world’s leading producers of rare earth metals and alloys, its magnet manufacturing capacity in Stillwater, Oklahoma, the planned acquisition of the Pela Ema mine in Brazil (subject to closing the Serra Verde Group transaction) and the Round Top deposit in Texas, USA Rare Earth operates across the entire value chain from mining to metal-making, alloy production and neodymium magnet manufacturing. USA Rare Earth is establishing a secure, Western supply of materials essential to the aerospace and defense, semiconductor, energy, data center, physical AI, mobility, healthcare and other key industrial sectors. For more information, visit www.usare.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those relating to the objectives, scope and anticipated benefits of the Wheat Ridge demonstration program; the Company’s ability to validate and optimize its processing and separation flowsheets and to produce separated oxides at commercial quality; the Company’s plans for a consolidated commercial separation facility for magnet swarf and mixed rare earth carbonate; and the Company’s global value chain strategy. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to risks and uncertainties and potentially inaccurate assumptions that could cause actual results to differ materially from the Company’s expectations, including without limitation: the Company’s ability to execute its business plan, including development of the Round Top deposit and its processing and manufacturing facilities; the timing and advancement of expected business milestones; the significant long-term and inherently risky investments the Company is making in mining and manufacturing facilities; the Company’s ability to obtain additional or replacement financing as needed; risks that the proposed transactions with Serra Verde Group, Carester SAS and Texas Mineral Resources Corp. may not be consummated on their anticipated timelines or at all; the Company may not realize the anticipated benefits of its proposed and prior acquisitions, including expected synergies, financial performance, estimated EBITDA and, in the case of Serra Verde Group, integration of operations, on the anticipated timeline or at all; the ability of the Company’s Stillwater facility or other future magnet manufacturing facilities to commence commercial operations on the timing and with the production capacity anticipated or at all; the Company’s limited operating history; risks that the Company may experience delays, unforeseen expenses, increased capital costs, and other complications in operating its business; potential dilution to existing stockholders and adverse effect on the Company’s stock price if the Company issues additional common stock or equity-linked securities; the volatility of the Company’s stock price; the Company’s ability to satisfy project milestones and other conditions to disbursement under the Company’s financing arrangement with the Department of Commerce (“DOC”) on the anticipated timeline or at all; the Company’s dependence on continued governmental support for the DOC financing transactions, which remains subject to changes in laws, regulations, administrations and appropriations; extensive affirmative and negative covenants, domestic content and national security guardrail provisions and ongoing reporting obligations in the DOC financing agreements that restrict the Company’s operational and financial flexibility; the risk that defaults under the DOC funding agreements could trigger cross-defaults across the Company’s financing arrangements; the impact of the DOC’s equity interest in the Company on the Company’s ability to pursue strategic transactions and on the Company’s relationships with customers, suppliers, partners and other counterparties; the availability of rare earth oxide, metal feedstock and other materials, utilities (including power and water) and equipment in quantities and prices that allow the Company to develop and commercially operate the Company’s Stillwater facility and other facilities; the Company’s ability to meet individual customer specifications and manufacture a consistently high quality product; fluctuations in demand for and prices of the Company’s products, including without limitation as a result of dumping, predatory pricing and other tactics by the Company’s competitors or state actors or the overall competitive environment; the Company’s ability to achieve positive cash flow or profitability or the ability to access cash flow within the Company’s corporate structure due to restrictions contained in the Company’s financing agreements; the Company’s ability to convert current commercial discussions and/or memorandums of understanding with customers for the sale of the Company’s neo magnets and other products into definitive orders; geopolitical developments or disruptions, such as changes in the political environment, export/import or environmental policy of the People’s Republic of China, the United States or other countries in which the Company operates or sells products or otherwise; war, terrorism, natural disasters or public health emergencies; the Company’s ability to retain or recruit key personnel; environmental, health and safety regulations; and the Company’s ability to comply with requirements for federal, state and local government incentives and financing.

Additional risks and detailed information regarding factors that may cause actual results to differ materially has been and will be included in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and subsequent filings. Any forward-looking statements speak only as of the date of this press release (or such other date as is specified in such statements), and the Company undertakes no obligation to update any forward-looking statements as a result of new information or future developments except as required by law.

Investor Contact
JB Lowe
Vice President, Investor Relations
USA Rare Earth, Inc.
[email protected]

Media Contact
Collected Strategies
[email protected]

SpaceX  (NASDAQ: SPCX) has erased approximately $1.2 trillion in market value within a month of its historic public debut, as a sharp selloff reversed much of the stock’s post-IPO rally.

The aerospace and satellite communications company went public on Nasdaq on June 12, 2026, at $135 per share, briefly reaching a market capitalization of nearly $2.9 trillion just four days later. 

However, the stock has since fallen sharply, reducing its valuation to about $1.83 trillion at Monday’s close.

The decline reflects growing investor concerns over SpaceX’s valuation following its record-breaking IPO and raises questions about whether the company’s long-term growth prospects can justify its current market capitalization.

Investor enthusiasm initially propelled SpaceX shares above $225 on June 16, making the company one of the world’s most valuable publicly traded firms. 

The rally proved short-lived, with the stock entering a sustained downtrend marked by several steep daily declines, including a 16% drop in a single session.

By July 13, SpaceX shares closed at $139 after falling more than 4% on the day, marking a new post-IPO low. At current levels, the stock trades only slightly above its $135 IPO price, leaving many investors who bought during the initial surge facing significant losses.

SpaceX one-month stock price chart. Source: Finbold Why SpaceX stock is declining The selloff comes as investors reassess SpaceX’s valuation and financial outlook after the excitement surrounding its market debut. 

The company generated $18.7 billion in revenue in 2025, up about 33% year-over-year, but reported a net loss of $4.9 billion as heavy spending on artificial intelligence infrastructure and Starship development weighed on profitability.

Starlink remains the company’s primary profit driver, contributing roughly $11.4 billion in revenue and serving more than 10.3 million subscribers as of the first quarter of 2026. 

Analysts expect SpaceX revenue to reach between $34 billion and $43 billion this year, supported by continued subscriber growth and expanding AI compute contracts.

At the same time, the Federal Aviation Administration has closed its investigation into the Starship Flight 12 anomaly, clearing the way for Starship Flight 13 as early as July 16. 

The mission is expected to deploy advanced Starlink V3 satellites and conduct additional reusability tests critical to SpaceX’s long-term growth strategy.

At the same time, concerns remain over insider share unlocks expected after second-quarter earnings in August, which could significantly increase the public float and add selling pressure.

Despite the sharp decline, SpaceX remains one of the world’s largest publicly traded companies. The stock’s next move will likely depend on the success of upcoming Starship milestones, Starlink’s continued expansion, AI revenue growth, and the company’s ability to balance aggressive investment with a path to profitability.

One month ago, on June 12, Elon Musk's artificial intelligence (AI) and space economy conglomerate, Space Exploration Technologies (SpaceX) (SPCX 4.75%), rewrote history with its initial public offering (IPO). The $85.7 billion raised, including the underwriters' overallotment, nearly tripled the previous IPO record holder, Saudi Aramco.

But in kicking off IPO mania -- large language model developers Anthropic and OpenAI are expected to follow in SpaceX's footsteps -- SpaceX may also be fueling the final stages of an AI bubble that history suggests is waiting to pop.

Rarely are stock market bubble warning signs as glaring as Raymond James Financial's price target assigned to SpaceX.

Image source: Getty Images.

Wall Street's high-water price target foresees SpaceX reaching $800 in 2031 Given that 21 underwriters helped bring SpaceX public and received shares for doing so, it should come as no surprise that Wall Street analysts have, as a whole, presented an overwhelmingly positive outlook for the company.

But Raymond James Financial analyst Brian Gesuale is a true outlier. His $800 price target by 2031 implies 451% upside, based on where SpaceX's shares ended on July 10, and assumes a valuation of roughly $10.5 trillion. For context, this would be more than double Nvidia's current market cap.

$SPCX-SPACEX COULD SOAR 440%, SAYS RAYMOND JAMES

Raymond James launched SpaceX coverage with a Strong Buy rating and a Street-high $800 target, implying 440% upside.

The bullish outlook is driven by Starship, Starlink, and SpaceX's potential as a global infrastructure giant....

-- *Walter Bloomberg (@DeItaone) July 9, 2026 Gesuale foresees SpaceX's full-year sales scaling from an estimated $38.5 billion in 2026 to approximately $837 billion by 2031. More importantly, earnings before interest, taxes, depreciation, and amortization (EBITDA) are projected to catapult from $17.7 billion in 2026 to $696 billion by 2031.

While there's no question that AI and the space economy are two of the hottest addressable opportunities on Wall Street, several headwinds suggest Gesuale's pie-in-the-sky price target is pure fiction and the sign of an end-stage bubble that's about to burst.

Image source: Getty Images.

SpaceX spotlights everything wrong with Wall Street Although the stock market is a long-term wealth-creating machine, it's prone to occasional bubble-bursting events. SpaceX's current $1.91 trillion valuation and Raymond James' $800 price target for the company spotlight everything that's wrong with Wall Street over the short term.

For starters, SpaceX hasn't demonstrated that its operating model is sustainable. While satellite-based broadband services provider Starlink is profitable, AI start-up xAI -- the segment responsible for the lion's share of SpaceX's $28.5 trillion addressable market -- is burning cash as Musk's company chases AI compute capacity.

NEWS: SpaceX disclosed in its S-1 that it sees a $28.5 TRILLION total addressable market, which the company calls "the largest actionable TAM in human history." pic.twitter.com/fglJuozEqL

-- Exec Sum (@exec_sum) May 21, 2026 Elon Musk also has a terrible track record of fulfilling lofty promises and innovative expectations. As CEO of Tesla, Musk proclaimed that 1 million robotaxis would be on public roads by the end of 2020, which never happened. He's also assured investors that Level 5 full self-driving is "one year away" annually for more than a decade. Musk continually overpromises and underdelivers.

SpaceX is likely to be haunted by historical precedent, as well. No company at the forefront of a game-changing technology has sustained a price-to-sales (P/S) ratio above 30 for any extended period. SpaceX is trading at roughly 50 times Gesuale's forecast sales for this year.

Lastly, every game-changing technology for more than three decades has navigated an early stage bubble-bursting event. These bubbles have formed because investors constantly overestimate the optimization timeline of innovations. It'll likely be years before SpaceX's solutions are optimized, making Raymond James' high-water price target highly unlikely.